Quinapril Hydrochloride
FDA-approved product (tablet, oral), marketed as Accupril, Quinapril Hydrochloride.
- Registered studies
- 33
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Diabetes mellitus
- Heart failure
- Hypertension
- Kidney failure
- Stroke
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Ace inhibitors, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae15.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
33registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Quinapril Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Enalapril MaleateExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BendroflumethiazideExisting use: Cardiovascular disease, Hypertension68.8% AI-predicted activityagainst M. tuberculosis9 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more68.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorothiazideExisting use: Cardiovascular disease, Chronic kidney disease, Congestive heart failure and 6 more68.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more68.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more68.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RiociguatExisting use: Hypertension, Idiopathic and/or familial pulmonary arterial hypertension, Pulmonary arterial hypertension and 1 more68.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TrichlormethiazideExisting use: Cardiovascular disease67.9% AI-predicted activityagainst M. tuberculosis1 registered study
- Promazine HydrochlorideExisting use: Psychosis67.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more67.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydroflumethiazideExisting use: Cardiovascular disease67.7% AI-predicted activityagainst M. tuberculosis1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy
NCT00295542 · start 2000-03
Registered record
- Registry ID
- NCT00295542
- Conditions
- Hypertension
- Interventions
- Ambulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan); beta blockers (including nebivolol, atenolol, carvedilol); diuretics (torasemide, indapamide, HTCZ) and doxazosin; Combination therapy in essential hypertension
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-03
- Completion
- 2009-04
- Enrolment
- 3,344
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionAmbulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) +3 morePhasePhase 4Registry statusCompletedManagement With Accupril Post Bypass Graft
NCT00269243 · start 1999-11
Registered record
- Registry ID
- NCT00269243
- Conditions
- CABG
- Interventions
- Quinapril
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 1999-11
- Completion
- 2005-05
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCABGInterventionQuinaprilPhasePhase 4Registry statusCompletedEfficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus
NCT03031834 · start 1999-01
Registered record
- Registry ID
- NCT03031834
- Conditions
- Diabetic Autonomic Neuropathy
- Interventions
- Quinapril
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 1999-01
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetic Autonomic NeuropathyInterventionQuinaprilPhasePhase 4Registry statusCompleted